New Publication Demonstrates ATH434 is NeuroprotectiveThe Multiple System Atrophy Coalition has compiled a list of over thirty potential treatments currently in development for MSA. The graphic below will enable you to see at a glance how far along they are in the drug development process. To assist you in finding more detailed information we’ve divided the list into Clinical Trials and Laboratory Studies. Explore the links below to learn more.
Remember to check back regularly to find out what’s new in the Multiple System Atrophy Treatment Pipeline and be sure to Sign Up Here for our newsletter mailing list to stay informed of the latest updates.
** New ** July 15, 2021: New Publication Demonstrates ATH434 is Neuroprotective
** New ** July 1, 2021: Alterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer’s and Parkinson’s
June 23, 2021: European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial
June 11, 2021: Updated Q&A on Verdiperstat
May 2021: Updates on Biohaven’s study to evaluate the efficacy and safety of BHV- 3241 (Verdiperstat)
April 21, 2021: ATH434 protects brain cells and improves motor function in Parkinsonian disorder
February 5, 2021: Biohaven Shares Verdiperstat’s Mechanism of Action
December 23, 2020: MODAG Initiates First-in-Patient Phase 1b Trial for Anle138b in Parkinson’s Disease
December 3, 2020: Inhibikase Advances Development Program for Multiple System Atrophy (MSA) Based on Demonstration of Key Role of c-Abl Kinase in MSA Neurodegeneration
November 16, 2020: Alterity Announces Approval of US Patent for Next Generation Compounds to Treat Neurodegenerative Diseases (ATH434)
November 6, 2020: Effect of the Initial Maintenance Dose of Droxidopa on Treatment Persistence in Patients With Neurogenic Orthostatic Hypotension
November 6, 2020: M-STAR, an Ongoing Phase 3 Study in Participants with Multiple System Atrophy–Baseline Characteristics (Verdiperstat)
October 27, 2020: Alterity commences enrolling Multiple System Atrophy patients in bioMUSE Study (ATH434)
October 16, 2020: IXICO and NYU Langone Health Sign Agreement to Develop Novel Imaging Markers in Multiple System Atrophy (Sirolimus)
September 24, 2020: Targeting α-synuclein by PD03 AFFITOPE® and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: clinical relevance
September 3, 2020: A Phase 1 Randomized Trial of Specific Active α‐Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy
August 4, 2020: New data independently confirms and extends laboratory findings and expands safety profile of ATH434 (PBT-434)
July 21, 2020: Biohaven Completes Enrollment Ahead of Timelines in International Phase 3 Clinical Trial of Verdiperstat in Multiple System Atrophy
July 1, 2020: Alterity Therapeutics meeting with US FDA provides development pathway for ATH434 (PBT-434)
April 30, 2020: MSA Coalition Blog – Caution When it Comes to Stem Cells for MSA
April 16, 2020: MSA Coalition Blog – Q & A about Verdiperstat Clinical Trial
April 14, 2020: Nilotinib Fails to Prevent Synucleinopathy and Cell Loss in a Mouse Model of Multiple System Atrophy.
March 18, 2020: Biohaven’s Verdiperstat Receives Fast Track Designation for the Treatment of Multiple System Atrophy
January 21, 2020: Stealth BioTherapeutics Initiates First-in-Human Study of SBT-272
January 14, 2020: European Commission approves Orphan Designation for Alterity’s lead drug candidate (PBT-434)
December 18, 2019: MODAG Initiates First-in-Human Phase 1 Clinical Trial for Anle138b
December 18, 2019: Nilotinib Study Results Show People with Parkinson’s Disease Should Pass on This Drug
November 18, 2019: FTY720-Mitoxy reduces synucleinopathy and neuroinflammation, restores behavior and mitochondria function, and increases GDNF expression in Multiple System Atrophy mouse models. (Fingolimod)
November 4, 2019: Researchers begin trial of drug to slow progression of neurodegenerative condition Multiple System Atrophy (Exendin-4)
October 5, 2019: A vaccine for Parkinson’s disease shows promising results (PD01A)
August 2, 2019: Green Tea Extract Shows No Significant Benefit for Multiple System Atrophy (ECGC)
CLINICAL TRIALS & STUDIES
EXPERIMENTAL LAB WORK
Are you interested in participating in a clinical trial? Visit www.clinicaltrials.gov, enter the name of the disease and you’ll be able to stay abreast of the latest clinical trial news. You can also enroll in the Fox Trial Finder which not only allows you to share your information for future research studies but will also inform you of any research study or clinical trial for which you qualify.
More MSA Research Highlights
In this video, recorded at the MSA Coalition’s annual conference in September 2019, Dr. Gregor Wenning, Chairman of the MSA Coalition’s Scientific Advisory Board discusses MSA Coalition funded research and promising treatments to watch.
A Track Record of Success
Explore reports and articles from MSA Coalition supported research.
Building Hope Through Research
Since 2013, the Multiple System Atrophy Coalition has funded 42 MSA focused research projects for a total of $2 Million.
Explore the links below to learn more about our research goals and the outcomes of our funded projects.
The 42 projects cover four major themes:
- Pathogenesis: Uncovering the cause of MSA
- Diagnostic Biomarkers: Improving methods for better diagnosis
- Preclinical: Evaluating potential new treatments in the lab
- Clinical: Facilitating clinical studies of potential new treatments in MSA patients
We are making an impact!
- See slides of the latest research results from our funded projects
- Explore the MSA treatment pipeline, including links to current clinical trials
- Check out the growing number of peer reviewed research articles that have arisen from our MSA Coalition funded grants.
© Copyright The Multiple System Atrophy Coalition 1989-2021. All Rights Reserved.